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1. Introduction 
The use of light-driven imaging techniques for the diagnosis of breast cancer dates back to 
as early as 1929. Transillumination was evaluated for potential differentiation of breast 
lesions, e.g. to distinguish benign cysts from solid tumours. Cutler summed the technique to 
be “...a simple procedure and a valuable aid in the interpretation of pathological conditions 
in the mammary gland. Its use is recommended in the routine examination of the 
breast...”(Cutler, 1929, 1931).  
 
 
Fig. 1. Opacity on transillumination of a solid tumour in the breast (Cutler, 1931, reproduced 
with permission from Wolters & Kluwer). 
At the same time, x-ray mammography emerged, routinely used for detection and diagnosis 
of breast cancer from the 1950s (Leborgne, 1951). Only relatively low sensitivity and 
specificity of mammography findings in combination with significant x-ray exposure 
though always triggered the parallel search for alternative diagnostic approaches. Over the 
following years, the use of near infrared (NIR) light was discussed to further facilitate 
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transillumination of breast tissue (Watmough, 1982a; Watmough, 1982b). Its unique 
characteristics regarding interaction with tissue - low absorption and reduced scattering – 
enable NIR light to travel through tissue and thus to reach deep tissue sections, therefore 
defining a valuable tool in diagnostic optical imaging (OI) techniques (Weissleder & 
Ntziachristos, 2003). Originating from transillumination, diffuse optical tomography (DOT) 
was initially thought to be capable of identifying tumour formation in anatomical regions 
accessible to NIR light, as tumour tissue is characterized by distinct optical properties, based 
on altered tissue architecture, blood flow and oxygen consumption. However, the 
limitations of this technique, especially the limited spatial resolution, have been illustrated 
in several publications. Although the advances on the field of instrumentation were 
significant, first clinical studies in breast cancer patients proved discriminating lesions 
regarding their malignant potential reflected by their absorption characteristics still to be 
challenging (Boas, 1997). To further improve the specificity of OI, fluorescence contrast 
agents, fluorophores operating in the NIR range of the spectrum, have been used. Three 
different types of optical probes are currently available for clinical or preclinical (basic 
research) purposes – unspecific, specific and so-called smart probes. The only clinically 
approved fluorochrome, indocyanine green (ICG) is an unspecific, perfusion-type contrast 
agent. First promising results of ICG-driven DOT for detection and differentiation of breast 
lesions have recently been published, confirming sensitivity and specificity (Ntziachristos et 
al., 2000). So far restricted to preclinical use only, specifically binding optical contrast agents, 
targeted on key-structures of cancer cells, allow for disease specific imaging and in vivo 
characterization of lesions down to the molecular level. As state of the art anatomical 
imaging frequently fails in detecting early effects of modern anti-tumour therapy, contrast 
agents targeted to different tumour cell epitopes have been described and used to 
sensitively detect the molecular characteristics of malignant lesions and their alteration 
under therapy (Achilefu, 2004; Achilefu et al., 2000; Becker et al., 2001). So called smart 
probes even increase sensitivity and specificity of OI. Fluorescence characteristics of these 
probes change upon interaction with specific target structures, e.g. proteinases, therefore 
allowing detection of vital, invasive tumour lesions with unrivalled sensitivity (Bremer et 
al., 2001c; Bremer et al., 2002). This review gives an overview about the approaches, recently 
made on the field of optical tracer development and evaluation with a focus on targets 
relevant for breast cancer diagnosis and characterization. Especially the visualization of 
angiogenesis as a key process in tumour progression is emphasized. Many factors that are 
involved in angiogenic events have been evaluated over the last decades and are now well 
understood. Several growth factors, their receptors and diverse pathways triggering their 
expression, are crucially involved in cancer progression and metastasis. Moreover some 
proteinases, especially matrix metalloproteinases (MMPs) and cathepsins, proved to 
contribute to tumour growth by e.g. degradation of extracellular matrix (ECM) components. 
Clinical translation of the efforts made in the past recent years will be the main challenge for 
researchers active on the molecular imaging field. 
2. Instrumentation 
Technically, optical imaging is based on the detection of light and the visualization of 
photon distribution in tissue. While visible light (380-700 nm) is almost completely 
absorbed, scattered and reflected in the uppermost sections of tissue already, light of the 
NIR range of the spectrum can be facilitated for in vivo imaging approaches. Light of around 
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650 – 950 nm is absorbed to a much lesser extent than light of lower wavelengths and can 
thus be detected in deeper tissue sections (Ntziachristos et al., 2003). Moreover, 
autofluorescence of tissue is minimal in this so called optical window (Fig. 2), resulting in a 
higher signal-to-background ratio for near infrared images (Bremer et al., 2001b). 
 
 
Fig. 2. The optical window between 650 and 950 nm, where absorption by water 
haemoglobin and deoxyhaemoglobin is minimal. 
For non-enhanced optical imaging approaches, simple opposed lightsource detector pairs 
are used. Light is applied to the scan volume at a distinct place and the detector is used to 
collect the non-absorbed photons. Highly absorbing lesions (e.g. tumour lesions) are 
supposed to delineate as negative contrast. Diffuse optical tomography (DOT) is based on 
the same principle, creating 3D absorption maps from e.g. the female breast (Ntziachristos et 
al., 2000; O'Leary et al., 1995). Commercially available optical imaging devices use adapted 
light for dye excitation; in experimental settings ultrasound was alternatively used 
successfully for the excitation of fluorophores (Razansky et al., 2008; Yuan & Liu, 2010). 
Fluorescence-producing proteins, encoded by so-called imaging target genes can either be 
light-excitable or metabolism-dependent, producing fluorescence upon interaction with 
exogenous substrates (Chudakov et al., 2010; Lukyanov et al., 2010). All dyes regularly used 
for targeted in vivo imaging require excitation with light of distinct wavelength to produce a 
specific emission. An imaging unit therefore always consists of an excitation light source on 
the one hand and a signal recording camera on the other (Fig. 3). The animal is placed either 
between both for optical tomography (Fluorescence Mediated Tomography – FMT) or on 
the ground of an imaging chamber with light source and camera both on one side 
(Fluorescence Reflectance Imaging – FRI) (Mahmood et al., 1999; Weissleder et al., 1999). 
Reflectance imaging approaches in this context basically resemble traditional photography, 
allowing for acquisition of 2D image data at video rate with highly sensitive CCD cameras. 
Regularly, cameras are adapted with filter sets for each particular wavelength, virtually 
blocking diffuse background fluorescence. The image acquisition is preceded by 
illumination of the whole field of view with either light of distinctive wavelengths – adapted 
for the applied dye – or unfiltered, multi-wavelength light (Graves et al., 2004). The latter of 
course results in excitation not only of the applied dye but of virtually all substances capable 
of producing fluorescence. This circumstance contributes to the background signal and thus 
requires more sophisticated filter equipment at the signal recording side. Further increase of 
signal-specificity can be achieved by using excitation light of discrete wavelengths, using 
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e.g. filters or even more precisely laser-light. The main disadvantage of such laser-light 
equipped units is the reduced flexibility, as upgrading the system for detection of a new 
spectrum of dyes with different spectral characteristics would always require a new laser-
light source, which is usually much more expensive than a new set of filters for multi-
wavelength excitation devices. State of the art FRI systems frequently allow for fusion of 
fluorescence images with white-light and x-ray images. 
 
   
Fig. 3. Left: Typical FRI system for in vivo animal investigations. The illumination source and 
CCD camera are on the same side of the animal. Right: Example of an FMT scanner. The 
scanner uses multiple light sources and detectors to effectively collect light at multiple 
projections around the animal’s body (from Graves et al., 2004; Ntziachristos et al., 2003; 
reproduced with permission). 
Anatomical correlation of FRI results, though, is limited due to the basic imaging principle. 
Absorption and scattering of light in tissue hamper detection and correct visualization 
especially of such signals originating from deeper regions of the scan volume which may 
thus not be properly reflected by the signals obtained at the scan volume surface (Montet et 
al., 2005). Multi-angle imaging is frequently regarded as one possible solution for this 
general FRI limitation. First approaches on this field are promising regarding the propriety 
of signal-to-source correlation, but are still in a prototype stage. Moreover, multi-angle 
optical imaging does still not offer anatomical co-information and thus lacks the possibility 
to correct fluorescence signals for scattering and absorption yet. In first studies, combination 
of optical tomography and x-ray based computed tomography (CT) is used to overcome this 
limitation. CT is used to acquire anatomical information and thus to depict optical 
properties of tissue for more precise prediction of the origin of detected photons (Guo X. et 
al., 2010b; Nahrendorf et al., 2009). Commercially available FMT systems aim to solve this 
problem without additional anatomical data acquired by CT or MRI. A 2D scan matrix is 
excited point by point with dye-adapted laser-light while the resulting fluorescence signals 
are recorded on the other side of the animal. In a first step, the resulting fluorescence signals 
are used to calculate a scattering map of the scan volume. In a second step, the specific dye-
associated signals are recorded and a 3D dataset is calculated on the basis of the scattering 
map and presumptions about the optical properties of the examined tissue (Stasic et al., 
2003). The mathematical algorithm underlying this reconstruction of a 3D dataset from a 
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matrix of 2D data is based on the Born approximation to solve the wave equation (Vinegoni 
et al., 2009). The approach has been validated, using surgical implants of known 
concentrations of fluorescent dyes implanted into animals at defined points (Ntziachristos et 
al., 2002). The presumptions on optical properties of the heterogeneous tissue on the track of 
a single photon, though, can only be approximations and may cause inaccurate results in 
individual cases. Combination with established cross-sectional imaging for the creation of 
fusion images is on the way and may help to correct for those adverse results. Additionally, 
anatomical co-information will simplify interpretation of fluorescence signals, especially in 
complex models of disease.  
The more modern translation into patient diagnosis started with the development of the first 
clinical optical breast imaging systems. Companies and academia put a lot of effort in this 
task, and in addition to several prototype instruments, three systems are commercially 
available at the moment. The Computed Tomography Laser Mammography system 
CTLM®, developed by Imaging Diagnostic Systems Inc., is a fully tomographic system and 
generates volumetric images of the breast (http://www.imds.com/ctlm/). Poellinger 
(Poellinger et al., 2008) and Floery (Floery et al., 2005) have used the system for small study 
groups and concluded that CTLM could be used for the delineation of malignant tissue but 
should be seen as an adjunct to conventional mammography only. The ComfortScan® 
system, distributed by Danum International Ltd., is a transillumination system that requires 
breast compression to generate 2D-images (http://www.danum.com/comfortscan.html). 
Fournier and colleagues concluded that the system had the potential to distinguish benign 
from malignant lesions but were not certain about specificity of findings and finally 
assumed a higher number of false positive results compared to conventional mammography 
(Fournier et al., 2009). The SoftScan® system by Advanced Research Technologies Inc., is a 
system that requires slight breast compression but is able to generate tomographic images of 
the breast (http://www.art.ca/en/clinical/). Using this system, van de Ven performed a 
phantom study, testing contrast agents of different intensity. It was concluded that the use 
of such contrast agents, at best in addition to a targeting ligand, would have a great 
potential in future optical breast cancer diagnosis (van de Ven et al., 2011). Detectors for 
fluorescence signals can also be minimized and e.g. integrated in endoscopic devices. Jaffer 
in this context reported the use of intravascular NIRF imaging in murine models of 
atherosclerosis (Jaffer et al., 2008; Jaffer et al., 2009). 
3. Optical imaging of tissue perfusion 
Due to the fact that oxy- and deoxyhaemoglobin are mainly responsible for absorption of 
NIR light in tissue, non-enhanced OI, e.g. transillumination, has been explored for detection 
of breast cancer, reflected by elevated tissue perfusion (Hawrysz & Sevick-Muraca, 2000). In 
1931 already, Cutler described that naive transillumination diaphanography could help to 
identify breast cancer (Cutler, 1931). Decades later, DOT allowed for 3-D determination of 
scattering and absorption properties of tissue or turbid material, respectively. Both 
approaches nevertheless fail to provide sufficient physiological information for safe 
delineation of malignant lesions. And so, low specificity of imaging findings and reduced 
sensitivity for lesions in deeper tissue regions always promoted efforts to develop optical 
contrast agents. Proof-of-concept DOT mammography experiments employing ICG as a 
contrast-enhancing agent successfully showed that breast lesions could be delineated from 
healthy tissue, although the poor water-solubility and the resulting rapid liver-uptake 
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hampers the use of ICG in routine breast cancer imaging (Ntziachristos et al., 2000; Riefke et 
al., 1997). Other carbocyanine-based dyes with a more hydrophilic character were designed 
and employed in imaging experiments, as well. Especially SIDAG (1,1'-bis-(4-
sulfobutyl)indotricarbo-cyanine-5,5'-dicarboxylic acid diglucamide monosodium; Global 
Drug Discovery, Bayer Schering Pharma AG, Berlin, Germany) shows improved 
photophysiological and pharmacological characteristics. This dye was developed by Licha 
and co-workers in the mid-nineties (Licha et al., 1996, 2000; Riefke et al., 1997) and showed 
good target-to-background contrast in a number of different murine xenograft models (Fig. 
4), including breast cancer. A correlation of SIDAG-signal intensity to the vascular volume 
fraction of the tumour as an MRI-based parameter of angiogenic potential could be shown 
(Wall et al., 2008). 
 
 
 
 
Fig. 4. Comparison of perfusion-type fluorescent dye SIDAG application to differently 
vascularized tumours. White light images of different tumour xenografts (left row), 
followed by FRI images taken sequentially after application of 2 µmol/kg body weight 
SIDAG. There is a strong fluorescence signal in HT-1080 fibrosarcomas and in MDA-MB 435 
tumours, whereas MCF-7 and DU-4475 adenocarcinomas exhibit only moderate tumour 
fluorescence (modified from Wall et al., 2008, courtesy of the author). 
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Van de Ven et al. evaluated contrast-enhanced DOT, using Omocianine (Bayer Schering 
Pharma, Berlin, Germany), a novel fluorescent contrast agent, in a first clinical trial of 12 
patients suffering from BI-RADS 4–5 breast lesions, using MRI as reference modality and a 
Philips prototype DOT scanner. They observed dose-dependent enhancement in malignant 
lesions. The fluorophore allowed for a reliable detection of malignant lesions in the breast 
(Fig. 5). Limitations of this approach comprised the visualization of lesions close to the chest 
wall as well as the absence of clear anatomical landmarks for lesion localization (van de Ven 
et al., 2009, 2010). Just recently, Poellinger et al. in a larger study examined 52 patients with 
53 suspicious breast lesions (BI-RADS 4–5) by using the CTLM® system. In this placebo-
controlled, dose-escalating trial a detection rate of up to 100% (7 of 7 lesions) after injection 
of 0.1 mg/kg Omocianine has been reported (Poellinger et al, 2011). Overall, higher 
detection rates were achieved for larger lesions, at smaller breast sizes, and for cases in 
which the tumour was located closer to the skin. However, there were also limitations in 
this study including detection of additional lesions or reconstruction artefacts. 
 
 
Fig. 5. Contrast-enhanced DOT of the breast: Omocianine-enhanced DOT of a patient with 
invasive lobular carcinoma in the left breast (first row) with visible contrast agent 
accumulation in the region of the tumour. The contralateral breast (second row) showed no 
suspicious contrast enhancement. MRI corroborated the optically detected breast cancer 
lesions (bottom row) (van de Ven et al., 2010; reproduced with permission from Springer). 
In summary, perfusion-type fluorescence contrast agents like ICG, SIDAG or Omocianine 
(Fig. 6) facilitate a higher target-to-non-target contrast than simple transillumination 
techniques or non-enhanced DOT. Assuming a linear correlation of signal intensity and 
local tissue perfusion, contrast enhanced OI could provide quantitative data of tumour 
vascularization. The future use of these types of contrast agents and imaging procedures in 
clinical routine, either as an adjunct to or a replacement for x-ray mammography, strongly 
depends on legal approval and further refinement of this imaging technology. 
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Fig. 6. Molecular structures of ICG, Omocianine and SIDAG. 
4. Molecular targets 
Breast cancer (BC) is a heterogeneous class of disease, exhibiting a variety of phenotypes 
and molecular profiles. For selection of the most promising therapy with regard to the 
molecular profile of a cancer lesion, immunohistochemistry of e.g. biopsies is performed. In 
this context, identification of e.g. hormone receptor positive (estrogene, ER+, progesterone 
PR+) or human epidermal growth factor receptor 2 positive (HER-2+) cancers for receptor 
antagonist driven therapy is frequently possible. Antibody based therapy is routinely 
combined with classical chemotherapy after surgery for therapy of ER+ and HER-2+ 
tumours, significantly contributing to therapy success (Alvarez & Price, 2010; Alvarez et al., 
2010; Giovannini et al., 2010; Johnson & Brown, 2010; Parker & Sukumar, 2003; Rose & 
Siegel, 2010). Cancers devoid of the mentioned receptors, so-called triple negative breast 
cancers (TNBCs), therefore show a relatively poor prognosis due to reduced therapy options 
(De Laurentiis et al., 2010). Cell surface receptors are, however, not only a promising target 
for therapy but may also serve for early detection and in vivo characterization of breast 
cancer. Especially growth factors and their receptors, hormone receptors, proteases and 
integrines have been addressed as targets for diagnostic in vivo imaging. This article will 
give an exemplary overview of successfully performed molecular imaging approaches. 
4.1 Growth factors and their receptors 
Many cancer cell lines have been shown to produce different types of growth factors, 
promoting tumour growth and survival. The most prominent of these growth factors is the 
vascular endothelial growth factor (VEGF). A number of seven different growth factors of 
this family have been recognized, of which five have been found in human, including 
placenta growth factor (PlGF), which is responsible for angionenic processes during the 
menstrual cycle (Fig. 7). 
 
 
Fig. 7. Human VEGFs and their receptors. 
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Under physiological conditions, VEGF promotes angiogenesis and vasculogenesis in e.g. 
wound healing or muscle growth. VEGF expression is to a considerable extent induced by 
low oxygen supply. Hypoxia inducible factors (HIF-1 and -2) are the main determinants 
in this context, inducing VEGF mRNA transcription. Other elements enhancing VEGF 
expression are intracellular adenosine, interleukin-6 (IL-6) and transforming growth factor  
(TGF-. Signalling of VEGF is mediated by binding of these peptides to three closely related 
tyrosine kinase (TK) cell surface receptors (VEGFR-1, -2 and -3) which dimerize upon 
activation and induce endothelial cell (EC) proliferation, vascular remodelling and 
neovascularization (De Laurentiis et al., 2010; Gasparini, 2000; Giovannini et al., 2010; Guo S. 
et al., 2010a; Hasan & Jayson, 2001; Hendrix et al., 2000; Hicklin & Ellis, 2005). In patients, 
elevated expression of VEGF and/or its receptors is often associated with reduced event-
free or overall survival. Therefore anti-angiogenic therapy approaches targeting the VEGF 
system have been developed and tested in first clinical trials. The VEGF system can also be 
employed for the in vivo determination of receptor expression profiles of tumours in 
preclinical settings. In 2007 Backer et al. facilitated the use of a recombinant single chain 
protein construct (scVEGF) to image VEGFR expression in vivo by OI in combination with 
single photon emission computed tomography (SPECT) and positron emission tomography 
(PET). The Cy 5.5 labelled probe (scVEGF/Cy) was used to image human breast cancer cell 
line MDA-MB 231 and murine mammary tumour cell line 4T1, both transfected for 
luciferase expression for bioluminescence imaging (BLI), in nude mice. The tracer was 
shown to bind to tumour vasculature, even in barely palpable lesions, indicating an early 
influence of the VEGF system in the process of tumour progression. In both tumour models, 
Cy 5.5 fluorescence could be co-localized with immunofluorescence staining of VEGF 
receptors and CD31 (Fig. 8) (Backer et al., 2007). 
 
 
Fig. 8. NIRF imaging with scVEGF/Cy and localization of Cy5.5 on histological sections.  
(a) NIRF imaging and BLI of 4T1luc-tumour-bearing mouse injected intravenously with 
scVEGF/Cy or inactive control peptide inVEGF/Cy. (b) Co-localization of Cy5.5 
fluorescence and immunofluorescence staining for VEGFR-2 on 4T1luc tumour cryosections 
indicates the potency of the CY 5.5 labelled protein conjugate scVEGF/Cy for in vivo 
imaging of VEGF receptors. (Reproduced from Backer et al., 2007 with permission from 
Nature Publishing Group). 
Although the tracer showed a highly heterogeneous accumulation and retention, specific 
binding and consecutive internalization of the scVEGF-based agent by VEGF receptors in 
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the tumour area was assumed. Generally, it is recognized that the in vivo imaging of VEGF 
receptors will facilitate assessment of angiogenesis-related parameters for personalized 
treatment in the future. In another approach, the anti-VEGF monoclonal antibody 
bevacizumab (Avastin®), a therapeutic against diverse metastatic cancers used in the US 
since 2004, was labelled with a fluorescent dye and explored for the in vivo imaging of 
VEGF. The scintigraphic imaging of VEGF receptors employing 111In- and 89Zr-labelled 
bevacizumab conjugates is also discussed as a rapid technique to follow therapy response 
with SPECT and PET (Nagengast et al., 2007). 
Epidermal growth factor receptors (EGFRs) are closely related to VEGF-Rs, sharing their 
tyrosine kinase activity and their frequent presence on the cell surface of tumours, also 
promoting proliferation and cell-survival. Trastuzumab (Herceptin®) is a monoclonal 
antibody against human epidermal growth factor receptor 2 (HER-2). In 2004, fluorescently 
labelled Herceptin® has been used for the stratification of tumour lesions with regard to 
HER-2-expression. In vivo signals after application of the probe reflected the strong or 
moderate level of HER-2-expression of human breast cancer cell line SK-BR-3 (high HER-2-
expression) or human squamous cell carcinoma cell line PE/CA-PJ34 (mild HER-2-
expression) (Fig. 9, Hilger et al., 2004). 
 
 
Fig. 9. White light (a, c) and fluorescence images (em=694 nm, b, d) of xenografted mice 
after application of 100 µg Cy5.5-labelled Herceptin® in an SK-BR-3 tumour (a, b) and a 
PE/CA-PJ34 tumour (c, d). The highly expressing SK-BR-3 tumour clearly shows a distinct 
fluorescence signal compared to the normal expressing PE/CA-PJ34 tumour (arrows, 
modified from Hilger et al., 2004; reproduced with permission from Springer). 
Lee et al. have used engineered affibodies for HER-2 imaging (ZHER2:342). Affibodies are 
highly water-soluble -helical proteins, which can be produced from bacterial systems and 
have a high affinity for HER-2 besides a much smaller size compared to antibodies (20x) or 
antibody fragments (4x). In their study, three different types of HER-2-specific affibody 
molecules were conjugated with AlexaFluor dyes and compared with AlexaFluor–labelled 
trastuzumab in terms of affinity and specificity to the HER-2 receptor in vitro and in vivo. 
The human breast cancer cell line SK-BR-3 was used as positive control, xenografted in nude 
mice. Interestingly, in addition to the trastuzumab-AlexaFluor conjugate, only the dimeric 
form of the affibody coupled to an albumin binding domain (ABD) showed accumulation in 
the tumour region and could be used for the imaging of HER-2 in vivo (Fig. 10). Monomeric 
or simple dimeric forms of the affibody-AlexaFluor-conjugate showed a rapid renal 
clearance and therefore failed to accumulate in the tumour (Lee et al., 2008). 
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Fig. 10. In vivo NIR optical imaging of HER-2-expressing tumour xenografted mice after tail-
vein injection of the AlexaFluor 750 labelled conjugates, showing pseudocolor fluorescence 
images obtained after injecting trastuzumab-AlexaFluor 750, affibodyABD-(ZHER2:342)2-
AlexaFluor 750, or affibody ZHER2:342-AlexaFluor 750 conjugates. Images of trastuzumab-
Alexa Fluor 750 conjugate were taken 6 hrs after injection instead of 8 hrs (left 
column)(Modified from Lee et al., 2008; reproduced with permission from AACR). 
Human adenocarcinoma cell lines provide a huge variety of cell surface receptors. MDA-MB 
468, e.g. is an EGFR-positive cell line, while MDA-MB 435 is EGFR-negative. These two cell 
lines have been chosen to evaluate the performance of Cy5.5-labelled EGF in vivo. Ke et al. 
used a custom-made imaging device to examine mice bearing xenografts of these tumour 
types in the chest walls. A fluorescence signal could clearly be visualized in MDA-MB 468 
tumours, but not in MDA-MB 435 tumours. Specificity of binding could be confirmed by 
blocking experiments with anti-EGFR antibody C225 (cetuximab, Erbitux®) (Ke et al., 2003). 
A similar approach was used by Wang and Chen in 2009 (Wang K. et al., 2009). They 
labelled the, by now commercially available, antibody to generate Erbitux®-Cy5.5 as an 
EGFR imaging tracer. The xenograft model they used was also adenocarcinoma-based. 
MDA-MB 231 and MCF-7 were chosen as strong and moderate EGFR-expressing cell lines, 
respectively. Murine xenograft models of both tumour entities were imaged and the tracer 
was shown to specifically accumulate in tumour regions 24 hours after intravenous injection 
with the EGFR-overexpressing MDA-MB 231 tumour showing an about two-fold higher 
fluorescence signal than the only moderately EGFR-expressing MCF-7 tumour (Fig. 11). 
Again, specificity was proven by excess unlabelled antibody treatment (blocking). 
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Fig. 11. In vivo near-infrared (NIR) images of MDA-MB-231 and MCF-7 xenografted (arrows) 
nude mice at 24 hours post injection of Erbitux®-Cy5.5. The fluorescence signal is clearly 
visualized in the left thoracic tumour region of MDA-MB-231 and MCF-7 xenografts. 
Blocking experiments indicate an apparent decrease of the fluorescent signal by pre-
injection of excess Erbitux®, proving specificity (modified from Wang K. et al., 2009; 
reproduced with permission from InformaHealth).  
4.2 Hormone receptors 
Estrogen receptors (ERs) are over-expressed in around 70% of breast cancers, which are then 
referred to as ER-positive or hormone-dependent. Tamoxifen is the most frequently used 
anti-hormonal drug for treatment of women with hormone-dependent breast cancer. 
Tamoxifen treatment is very effective in these cases and significantly reduces the mortality 
of breast cancer patients. Unfortunately, during treatment many tumours develop a 
resistance to the drug, often accompanied by a reduction or loss of estrogen receptors. 
Several mechanisms have been discussed to be responsible for this development (Kumar 
2007) and a non-invasive imaging technology to detect ER expression in vivo could help 
identifying the underlying process. A recent approach from Jose and co-workers describes 
the labelling of estradiol with a carbocyanine dye for the evaluation of the hormone receptor 
status in vivo and could therefore help in decreasing the need for unnecessary biopsies. 
Future research will show the performance of the developed tracer in preclinical models 
(Jose et al., 2011). 
A rather particular system in this context is represented by the endothelin (ET)-axis, which 
is comprised of the three peptide hormones ET-1, ET-2 and ET-3 and their two associated 
receptors ETAR and ETBR. Endothelin (ET) was first described as a 21-amino acid peptide 
with vasoactive potency; in fact ET-1 is one of the most vasoconstricting substances 
currently known (Hickey et al., 1985; Yanagisawa et al., 1988). In addition to its role as a 
vasoconstrictor, more recently the role of the ET-axis as a progression factor in certain 
human cancers, including breast and ovarian cancer, has been discussed (Bhalla et al., 2009; 
Rosano et al., 2010). The influence of the ET-axis is attributed to elevated levels of ET-1 as 
well as overexpression of ET receptors on tumour cells and tumour associated cells (e.g. 
fibroblasts, endothelial cells, macrophages). In addition, a close interaction of the ET-axis 
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with EGFR/HER-2 signalling (Fischgräbe et al., 2009) and VEGF-induced angiogenesis 
(Kandalaft et al., 2010) has been found in breast cancers and consequently ET receptor 
antagonists as new chemotherapeutic drugs for cancer therapy have been introduced. The 
evaluation of the ET receptor status in vivo would allow for early diagnosis and clarify the 
impact of e.g. anti-angiogenic therapies. In 2007 our group reported the design of a small-
molecular ETAR antagonist conjugated to a fluorescent dye via a short polyethylene glycol 
spacer (Fig. 12), capable of imaging tumour-associated ETAR-expression in vivo (Höltke et 
al., 2007; Höltke et al., 2009). 
 
             
Fig. 12. Molecular structure of the designed fluorescent ETAR tracer (left). White light 
(middle) and merged x-ray and fluorescence (FRI) image (right) of tumour-associated ETAR 
expression in a murine breast cancer xenograft model 24 hrs after i.v. tracer administration 
(Höltke, unpublished results). 
4.3 Integrins 
Integrins are cell-adhesion proteins that mediate cell-cell and cell-extracellular matrix 
interactions, thereby increasing tumourigenicity and invasiveness of cancer. They are 
composed of an ǂ and a ǃ subunit. So far 24 ǂǃ combinations (ǂǃI) have been identified, 
seven of them have been demonstrated to bind the RGD motif, an arginine-glycine-aspartic 
acid-based peptide sequence (Arnaout, 2002; Arnaout et al., 2002; Hood et al., 2003; 
Schottelius et al., 2009). Also, the two ǂǃI known to be most active in tumoral 
neoangiogenesis, the vitronectin receptor ǂνǃ3 and the fibronectin receptor ǂ5ǃ1, bind RGD 
with high affinity. Integrin ǂνǃ3 is a transmembrane protein, which is specifically expressed 
on tumour surfaces and on activated and proliferating endothelial cells. In 1998, Gasparini 
and co-workers introduced vascular ǂνǃ3 as a prognostic factor in breast cancer (Gasparini 
et al., 1998). Soon after first RGD-based radiotracers for PET or SPECT were developed 
(Choe & Lee, 2007; Liu, 2006) fluorophore-labelled RGD derivatives were designed for NIR 
optical imaging approaches (Chen et al., 2004; Cheng et al., 2005; Gurfinkel et al., 2005; Ye et 
al., 2006). Since linear peptides containing the RGD sequence provide only low integrin 
subtype selectivity and are furthermore rather unstable under metabolic conditions cyclic 
RGD peptides were synthesized, which show a higher selectivity for ǂνǃ3 and are 
characterized by a sufficient metabolic stability (Fig. 13). 
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Fig. 13. Molecular structure of a typical cyclic RGD peptide conjugated to a fluorescent dye.  
First experiments with Cy 5.5-labelled RGD peptides were published in 2004 (Chen et al., 
2004; Wang W. et al., 2004) and aimed at glioblastoma, sarcoma and melanoma tumour 
entities. Besides the peptidic ǂνǃ3 ligands derived from RGD, antibodies, nanobodies and 
small molecular peptidomimetics have been presented (Winter et al., 2003; Winter et al., 
2006; Xie et al., 2008). In 2007, von Wallbrunn et al. visualized ǂνǃ3 activity in three different 
xenograft models, including breast cancer, using FRI and FMT (von Wallbrunn et al., 2007). 
Both modalities provided mutually correlating results, confirming histological gold 
standard measurements (Fig. 14, left). Recently, Mulder et al. presented an RGD-conjugated 
quantum dot (QD) for visualization of ǂνǃ3 expression in melanoma-bearing mice (Mulder 
et al., 2009). The QDs were coated with gadolinium diethylene-triaminepentaacetic acid 
(Gd-DTPA)-based lipids and therefore serving as bimodal imaging agents for a use in MRI 
and OI. In vivo examinations revealed an attachment of the QDs to tumour vessels after i.v. 
injection. Interestingly, a labelling of blood vessels as far as 1 cm outside the primary 
tumour lesion was observed, indicating activation of distant vascular endothelium. 
Confirming the specificity of binding to tumour vasculature, no significant accumulation of 
QDs in distant vessels of e.g. muscle was observed. The combination of MRI and 
fluorescence imaging allowed both exact anatomical localization and evaluation of 
angiogenic activity. In this study, luciferase-transfected tumour cells were used, providing 
bioluminescence images of the tumour for additional correlation of the QD-triggered 
imaging findings (Fig. 14, right). 
In summary, a large number of integrin-targeted optical probes have been developed and 
tested. Most approaches base on RGD-containing small peptides labelled with a fluorophore 
or conjugated to fluorescent nanoparticles (quantum dots). Many of these show promising 
results concerning sensitivity and specificity for tumour vasculature, demonstrating the 
potential of integrin targeting in cancer imaging. A representative review paper on the 
diverse structures of integrin targeted optical probes has recently been published, also 
touching the potential of integrin-based therapy (Ye & Chen, 2011). 
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Fig. 14. Two examples of recent integrin imaging approaches. Left: Fluorescence mediated 
tomography (FMT) images of different tumour entities 60 minutes after injection of a Cy 5.5-
labelled cyclic RGD peptide into athymic nude mice (2 nmol/animal), displaying tracer 
accumulation in the tumour lesion dependent on target structure expression and predosing 
(modified from von Wallbrunn et al., 2007, courtesy of the author). Right: MRI and OI of 
tumour-related angiogenesis visualized by ǂνǃ3 integrin-targeted multimodal QDs (pQDs): 
MRI, bioluminescence and FRI of a C57B16 tumour-bearing mouse before and after injection 
of RGD-pQDs. T2-weighed MR images (a,e) show the contour of the tumour on the flank. 
T1-weighted images were measured before (b,f) and 45 min after (c,g) the injection of the 
RGD-pQDs. The arrows in (c,g) indicate bright (positive contrast) regions in the periphery of 
the tumour. In d and h strong signal enhancement is colour-coded (red-orange). Correlative 
FRI (j) shows good co-localization of the signal with bioluminescence (i) of the tumour cells 
(reproduced from Mulder et al., 2009 with permission from Springer). 
4.4 Proteases 
Matrix metalloproteinases (MMPs) are closely connected to the pathophysiological 
properties of integrines, which also makes them relevant factors associated with tumour 
growth, progression and metastasis (Brooks et al., 1996; Chabottaux & Noel, 2007; 
Stefanidakis & Koivunen, 2006). Human MMPs are a family of 24 structurally related zinc 
ion-dependent endopeptidases, able to degrade almost all components of the extracellular 
matrix (ECM) and the basal membrane. Moreover, they contribute to the morphogenesis of 
endothelial cells and have been shown to regulate the transcription of growth factors. The 
large number of MMPs and their diverse routes of involvement in cancer progression have 
made it difficult to address their activity in therapeutic interventions. First clinical trials 
with broad-spectrum MMP inhibitors like Marimastat or Batimastat were discontinued 
because of poor performance and severe side effects (Dorey, 1999; Renkiewicz et al., 2003). 
In this respect, especially the gelatinases MMP-2 and MMP-9 were identified as diagnostic 
factors in breast cancer on both, their local and systemic level, frequently predicting lymph 
node involvement and metastatic status (Jezierska & Motyl, 2009; Radisky E.S. & Radisky 
D.C., 2010). The in vivo assessment of MMP activity would be highly desirable for diagnosis 
and the evaluation of therapy. Bremer et al. have developed a fluorescently labelled 
substrate probe for MMP-2 (Bremer et al., 2001a; Bremer et al., 2001c). A graft copolymer, 
consisting of a poly-lysine backbone and polyethylene glycol side chains, was equipped 
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with Cy 5.5 labelled specific peptidic substrates cleavable by MMP-2. Due to the close 
proximity of the dyes their fluorescence is quenched by the transfer of electronic excitation 
energy between two (or more) molecules (fluorescence resonance energy transfer, FRET) 
(Kiyokawa et al., 2006). Upon cleavage of the peptidic substrate by MMP-2 the dye 
molecules are removed from the backbone polymer, their fluorescence is dequenched and a 
signal can be detected. The resulting signal to background ratio is unrivalled due to 
virtually absent background fluorescence. (Fig. 15). 
 
 
Fig. 15. Principle of the use of FRET for the detection of proteolytic activity. When dye 
molecules are in close proximity to each other, the fluorescence is quenched by FRET (black 
circles). After cleavage of the peptide substrate by e.g. MMP-2 (scissors) fluorescence can 
emerge (red circles). Modified from Bremer et al., 2001a, courtesy of the author. 
The probe was applied to xenograft models of human fibrosarcoma HT-1080 and human 
breast adenocarcinoma BT-20. While HT-1080 cells express a high amount of MMP-2, BT-20 
cells show only moderate protease levels. Accordingly, in vivo examinations show strong 
fluorescence signals from HT-1080 tumours, compared to only low signals from BT-20 
xenografts (Fig. 16). 
 
 
Fig. 16. Demonstration of protease activity by NIRF imaging in murine xenograft models of 
MMP-2 positive human fibrosarcoma HT-1080 and MMP-2 negative adenocarcinoma BT-20. 
A: Colour photograph of the implanted nude mouse. Both tumours measured 
approximately 2 x 3 mm. B: The NIRF image shows that the fibrosarcoma generated strong 
fluorescent signal intensity 2 hours after i.v. injection of the MMP-2–sensitive probe, but the 
signal intensity of the BT-20 tumour was only slightly higher than background fluorescence 
(modified from Bremer et al., 2001a, courtesy of the author).  
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The method has also been successfully applied for the imaging of cathepsins (Bremer et al., 
2002). Cathepsins represent another group of proteases involved in cancer progression and 
the growth of metastases. Like MMPs, cathepsins comprise a large group of proteins 
responsible for a variety of processes in the animal/human body. Unlike MMPs, cathepsins 
do not depend on a Zn-atom at the active site, but are serine, cysteine or aspartate 
dependent. Most cathepsins are lysosomal proteins, activated by the low pH value inside 
the organelle. In particular cathepsins B, D, K and L2 have been assigned a role in breast 
cancer development and metastasis (Duffy, 1996; Nomura & Katunuma, 2005; Radisky E.S., 
2010; Rose & Siegel, 2010). In the presented examination, a cathepsin B sensitive probe was 
designed and used to distinguish a highly invasive (DU-4475) and a well differentiated 
adenocarcinoma (BT-20). The less invasive tumour showed a significantly lower 
fluorescence signal (- 35%) than the highly invasive one (Bremer et al., 2002).  
5. Conclusion  
The successful preclinical application of optical imaging methods for cancer imaging has 
been extensively demonstrated over the last years. Especially in small animal imaging, 
techniques for tumour characterization (e.g. surface target expression or vascularization) 
have been developed and validated. The synthesis of specific tracers for targets arising from 
the ever-growing pathophysiological understanding of diseases can easily be performed and 
does not require large-scale laboratory equipment. This enables more and more scientists to 
accelerate their research on targeted in vivo imaging. In addition, OI devices offer quick and 
convenient image acquisition and reconstruction, especially compared to other small animal 
imaging technologies. In basic research, OI of breast cancer is a well established part of 
everyday work.  Future use of OI in clinical routine depends on several factors, amongst 
which probe design and approval and further improvement of the imaging techniques 
appear the most important. For the elaboration of both factors, industry – either 
pharmaceutical- or medical technology companies – is required to partner with academic 
research institutions. On the technical side, spatial resolution and access to deep tissue 
lesions are the most striking and obvious points, where the refinement of techniques has to 
focus on. Pioneering work in this area is accomplished by the companies already 
distributing optical breast scanners. First trials with smaller groups of patients showed 
promising results, although by today the technique has to be considered an adjunct to 
conventional x-ray mammography only. On the field of tracer development, simple 
perfusion tracers, targeted fluorescent ligands, protease-sensitive smart probes and 
fluorescent nanoparticles or a combination of these still struggle for highest diagnostic 
accuracy on the one hand versus applicability on the other. It remains to be seen, whether 
targeted imaging will make the way into clinical routine and which role OI can play in this 
context. From the vast variety of targets relevant for basic research imaging, the 
identification of few molecular markers, expressed by a wide range of cancer entities seems 
to be a promising first step towards targeted molecular imaging, especially with regard to 
the immense regulatory effort and major investments (toxicology studies, GMP-production 
facilities etc.), which approval of a contrast agent requires. The existence of ICG on the 
market, though, substantiates the general possibility and shows that there is a demand for 
optical imaging contrast agents in the clinics and an increasing interest for further 
development in this field of alternative imaging technologies.  
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